Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Adult Solid Neoplasm Clinical Trial

Official title:

Phase I Trial of OSI-774 and CPT-11 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00045201
• Other study ID #: NCI-2009-00015
• Secondary ID: NCI-2009-00015CD
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: June 13, 2002
• Est. completion date: August 22, 2024

Study information

• Verified date: February 2024
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I trial to study the effectiveness of combining erlotinib hydrochloride with irinotecan hydrochloride in treating patients who have advanced solid tumors. Erlotinib hydrochloride may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib hydrochloride and chemotherapy may kill more tumor cells.

Description:

OBJECTIVES:

I. Determine the maximum tolerated dose (MTD) of erlotinib (erlotinib hydrochloride) and irinotecan (irinotecan hydrochloride), in relation to presence or absence of UGT1A1*28 polymorphism, in patients with advanced solid tumors that overexpress epidermal growth factor receptor.

II. Determine the dose-limiting toxicity of these regimens in these patients. III. Determine whether erlotinib alters the disposition of irinotecan using a previously described limited sampling model.

IV. Determine factors that influence the disposition of these drugs, including genetic variation in UGT1A1 and BCRP, in patients treated with these regimens.

V. Determine factors that influence the disposition of these drugs, in terms of tumor BCRP-expression, in tumor samples from patients treated with these drugs at the MTD.

VI. Evaluate the effect of this regimen on epidermal growth factor receptor phosphorylation in these patients.

VII. Assess, preliminarily, any antitumor activity in patients treated with these regimens.

VIII. Correlate, preliminarily, EGFR phosphorylation and/or BCRP -expression with response in tumor samples from these patients.

OUTLINE: This is a dose-escalation study. Patients are stratified according to UGTA1A genotype (all patients regardless of genotype [closed to accrual as of 9/15/04] vs UGT1A1 6/6 genotype vs UGTA1A 6/7 or 7/7 genotype).

Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride intravenously (IV) over 90 minutes on day 1 and oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients per stratum receive escalating doses of erlotinib hydrochloride and irinotecan hydrochloride until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Additional patients are treated at the MTD.

Patients are followed for 3 months.

Other known NCT identifiers

• NCT01646892
• NCT01664286

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: August 22, 2024
• Est. primary completion date: September 13, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed malignancy that overexpresses epidermal growth factor receptor (EGFR)

• Unresectable disease for which there is no known standard therapy that ispotentially curative or definitely capable of extending life expectancy

• UGT1A1 genotype 6/6, 6/7, or 7/7

• Willing to provide biologic specimens

• Lesions amenable for 2 biopsies from the same tumor site (only patients receiving MTD in groups 2 and 3)

• No known brain metastases

• Performance status - ECOG 0-2

• At least 12 weeks

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Hemoglobin at least 9.0 g/dL

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)

• AST = 2.5 times ULN (5 times ULN if liver metastases present)

• Creatinine no greater than 1.5 times ULN

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• No New York Heart Association class III or IV heart disease

• No gastrointestinal tract disease resulting in an inability to take oral or nasogastric medication

• No requirement for IV alimentation

• No active peptic ulcer disease

• No abnormalities of the cornea (e.g., dry eye syndrome or Sjögren's syndrome)

• No congenital abnormality (e.g., Fuch's dystrophy)

• No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)

• No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test)

• No other uncontrolled concurrent illness

• No ongoing or active infection

• No significant traumatic injury within the past 21 days

• No seizure disorder

• No psychiatric illness or social situation that would preclude study compliance

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No concurrent grapefruit or grapefruit juice

• No smoking during study

• More than 4 weeks since prior immunotherapy or biologic therapy

• No concurrent immunotherapy

• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

• No other concurrent chemotherapy

• Not specified

• More than 4 weeks since prior radiotherapy

• No prior radiotherapy to more than 25% of bone marrow

• No concurrent radiotherapy

• More than 3 weeks since prior major surgery

• No prior surgical procedures affecting absorption

• No prior EGFR-targeting therapy (e.g., gefitinib or EKB-569)

• No other concurrent investigational therapy

• No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine, or valproic acid)

• No concurrent combination antiretroviral therapy for HIV-positive patients

• No concurrent enrollment on another study involving pharmacological agents for symptom control or therapeutic intent

Related Conditions & MeSH terms

• Adult Solid Neoplasm

Intervention

Drug:
• Erlotinib Hydrochloride
Given orally
• Irinotecan Hydrochloride
Given IV

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD of erlotinib hydrochloride and irinotecan hydrochloride in patients with advanced solid tumors that overexpress epidermal growth factor receptor	Defined as the highest safely tolerated dose where at most one patient experiences DLT with the next higher dose having at least 2 patients who experience DLT. Three patients will be entered at a given dose level and observed for at least 4 weeks to assess toxicity. MTD will be determined independently for each cohort.	At least 4 weeks
Primary	Dose limiting toxicity of the combination in all cohorts	Defined as an adverse event attributed (definitely, probably, or possibly) to the study treatment. Graded using the National Cancer Institute Common Toxicity Criteria (CTC) version 2.0. Defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE) versioun 4.0.	At least 4 weeks
Primary	Effect of erlotinib hydrochloride on the disposition of irinotecan hydrochloride	Analysis performed using high performance liquid chromatography assays. Serial blood samples will be obtained during Cycle 1 only to determine the pharmacokinetics of irinotecan hydrochloride and erlotinib hydrochloride.	Weekly during course 1
Primary	Effect of erlotinib on EGFR phosphorylation at MTD		Weekly during course 1
Primary	Genetic variation in UGT1A1 and BCRP	Detected using allele-specific restriction fragment length polymorphism (RFLP) assays and GeneScan assays. The overall incidence of UTG1A1 polymorphism will be estimated and summarized.	Weekly during course 1
Primary	Tumor BCRP expression in patients treated at the MTD		Weekly during course 1
Primary	Evidence of anti tumor activity	Evaluated using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria.	Every 3 weeks
Primary	Correlation of EGFR phosphorylation and/or BCRP expression with response to this combination	Evaluated using modified RECIST criteria.	Every 3 weeks